1. Medtech Insight
  2. >>Business

Beta Bionics Secures $100M In Series D Funding To Expand Artificial Pancreas Tech

 
• By Marion Webb

After receiving US FDA clearance in May, Beta Bionics secured $100m in financing which is expected to be used to commercialize its iLet Bionic Pancreas and “further develop and test the bi-hormonal bionic pancreas.”  

Piggybank
• Source: Shutterstock

Beta Bionics, Inc. announced on 30 August that it has secured $100m in series D equity funding, which will be used to commercialize its newly US Food and Drug Administration-cleared iLet artificial pancreas technology and to further develop and test the bi-hormonal bionic pancreas.

Sands Capital and Omega Funds co-led the financing, which participation from previous backers Soleus Capital, Eventide Asset Management LLC, Farallon Capital, Perceptive Advisors, certain funds managed by RTW Investments, LP,...

More from Financing

More from Business

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By Shubham Singh

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.